A Phase 3 interventional study of Evolocumab and Placebo in Hyperlipidemia, sponsored by Amgen. Completed at 39 sites in 14 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-06-17.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing evolocumab in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. evolocumab · Hypercholesterolemia.
Among the 36 studies testing evolocumab in Hypercholesterolemia, this one is the 16th largest by enrollment, is one of 11 that started in 2013, is one of 22 in phase 3, and was the 9th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 36 studies testing evolocumab in Hypercholesterolemia is open now. Recruiting first, the newest first:
evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 24 · Phase 4 7
First in 2011; this study’s year is marked. 11 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 331 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 308 across the 36 interventional studies. Of the 32 that completed or were terminated, 31 (97%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 36 have an industry lead sponsor. The 6 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
35 studies in Hypercholesterolemia by Amgen: 1 open now, 1 under way, none of them phase 3. Of 34 finished, 30 (88%) have results posted.
Among the 35 studies in Hypercholesterolemia by Amgen, this one is the 16th largest by enrollment of the 31 interventional ones that give a count, is one of 11 that started in 2013, is one of 22 in phase 3, and was the 9th registered.
Amgen’s Hypercholesterolemia studies by the year they started, since 2011.
None of the studies under way reaches primary completion within a year.
Among the 36 studies testing evolocumab in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 35 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective was to evaluate the effect of 12 weeks of evolocumab subcutaneously once every 2 weeks (Q2W) and once monthly (QM), compared with placebo, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in adults with heterozygous familial hypercholesterolemia (HeFH).
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
This study's enrollment of 331 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Browse Hypercholesterolemia studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Compared within Hypercholesterolemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hyperlipidemias. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for up to 12 weeks.
Drug: Placebo
Participants received placebo subcutaneous injection once every month (QM) for up to 12 weeks.
Drug: Placebo
Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.
Biological: Evolocumab
Participants received 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.
Biological: Evolocumab
Administered by subcutaneous injection
Also known as: AMG 145, Repatha
Administered by subcutaneous injection
Percent Change From Baseline in LDL-C at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Change From Baseline in LDL-C at Week 12
Time frame: Baseline and Week 12
Percentage of Participants With Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL (1.8 mmol/L)
Time frame: Weeks 10 and 12
Percentage of Participants With LDL-C < 70 mg/dL (1.8 mmol/L) at Week 12
Time frame: Week 12
Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in Non-HDL-C at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in Apolipoprotein B at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in Lipoprotein (a) at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in Triglycerides at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in HDL-C at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol (VLDL-C) at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in VLDL-C at Week 12
Time frame: Baseline and Week 12
Men and women 18 to 80 years old with a diagnosis of heterozygous familial hypercholesterolemia (HeFH) on stable doses of an approved statin with fasting low-density lipoprotein cholesterol (LDL-C) ≥ 100 mg/dL were eligible for this study. The first participant enrolled on 07 February 2013 and the last participant enrolled 03 September 2013.
| Milestone | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Started | 55 | 55 | 111 | 110 |
| Received treatment | 54 | 55 | 110 | 110 |
| Completed | 49 | 54 | 101 | 108 |
| Not completed | 6 | 1 | 10 | 2 |
| Withdrew: Withdrawal by subject | 2 | 1 | 1 | 2 |
| Withdrew: Sponsor decision | 4 | 0 | 9 | 0 |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in LDL-C at Week 12 | -2.02 ± 2.49 | 5.53 ± 3.25 | -61.25 ± 1.77 | -55.74 ± 2.25 |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12 | -1.08 ± 2.41 | 2.30 ± 2.41 | -61.23 ± 1.71 | -63.25 ± 1.70 |
| mg/dL | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Change From Baseline in LDL-C at the Mean of Weeks 10 and 12 | -6.5 ± 4.2 | -1.3 ± 4.1 | -101.7 ± 3.0 | -98.8 ± 2.9 |
| mg/dL | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Change From Baseline in LDL-C at Week 12 | -8.5 ± 4.2 | 4.1 ± 5.2 | -101.3 ± 3.0 | -87.2 ± 3.6 |
| percentage of participants | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percentage of Participants With Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL (1.8 mmol/L) | 1.9 (0.3 to 9.9) | 1.9 (0.3 to 9.8) | 67.0 (57.7 to 75.1) | 80.4 (71.9 to 86.8) |
| percentage of participants | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percentage of Participants With LDL-C < 70 mg/dL (1.8 mmol/L) at Week 12 | 2.0 (0.3 to 10.3) | 2.2 (0.4 to 11.3) | 68.3 (58.8 to 76.4) | 63.1 (53.5 to 71.8) |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 10 and 12 | 0.21 ± 2.29 | 2.72 ± 2.21 | -55.79 ± 1.63 | -57.28 ± 1.56 |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 12 | -1.39 ± 2.40 | 5.29 ± 2.94 | -56.19 ± 1.71 | -49.67 ± 2.04 |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12 | -0.19 ± 2.10 | 2.21 ± 1.97 | -49.58 ± 1.48 | -52.76 ± 1.36 |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B at Week 12 | -0.67 ± 2.32 | 4.60 ± 2.70 | -49.75 ± 1.63 | -44.81 ± 1.80 |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12 | 0.86 ± 2.05 | 4.14 ± 2.13 | -45.74 ± 1.45 | -45.02 ± 1.50 |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12 | 0.12 ± 2.19 | 7.11 ± 3.13 | -45.95 ± 1.56 | -38.32 ± 2.15 |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12 | 0.78 ± 2.21 | 1.65 ± 2.35 | -52.39 ± 1.56 | -53.91 ± 1.60 |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12 | 1.54 ± 2.49 | 4.23 ± 3.66 | -52.74 ± 1.75 | -45.31 ± 2.42 |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 10 and 12 | 7.34 ± 2.97 | 5.35 ± 2.95 | -24.03 ± 2.09 | -25.65 ± 2.07 |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Lipoprotein (a) at Week 12 | 8.68 ± 3.27 | 6.69 ± 3.16 | -22.89 ± 2.31 | -21.55 ± 2.17 |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12 | 9.09 ± 3.02 | 7.49 ± 3.26 | -13.27 ± 2.14 | -9.25 ± 2.27 |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Triglycerides at Week 12 | 3.50 ± 3.51 | 6.43 ± 4.15 | -16.09 ± 2.49 | -5.13 ± 2.84 |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12 | -0.45 ± 1.70 | -2.86 ± 1.84 | 7.93 ± 1.20 | 6.62 ± 1.29 |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in HDL-C at Week 12 | -1.15 ± 1.91 | -3.73 ± 2.35 | 8.05 ± 1.35 | 5.35 ± 1.62 |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol (VLDL-C) at the Mean of Weeks 10 and 12 | 8.66 ± 2.90 | 6.34 ± 3.27 | -13.97 ± 2.06 | -9.20 ± 2.27 |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in VLDL-C at Week 12 | 3.73 ± 3.50 | 4.10 ± 4.17 | -17.25 ± 2.48 | -5.06 ± 2.84 |
Collected over From the first dose of blinded investigational product until the end of the study (up to 14 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Q2W | — | 2/54 (3.7%) | 5/54 (9.3%) |
| Placebo QM | — | 3/55 (5.5%) | 10/55 (18.2%) |
| Evolocumab Q2W | — | 3/110 (2.7%) | 17/110 (15.5%) |
| Evolocumab QM | — | 4/110 (3.6%) | 24/110 (21.8%) |
| Event | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Coronary artery diseaseCardiac disorders | 1/54 | 0/55 | 0/110 | 0/110 |
| Inguinal herniaGastrointestinal disorders | 1/54 | 0/55 | 0/110 | 0/110 |
| Blood creatine phosphokinase increasedInvestigations | 0/54 | 1/55 | 0/110 | 0/110 |
| DepressionPsychiatric disorders | 0/54 | 1/55 | 0/110 | 0/110 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/54 | 1/55 | 0/110 | 0/110 |
| Acute myocardial infarctionCardiac disorders | 0/54 | 0/55 | 1/110 | 0/110 |
| Angina pectorisCardiac disorders | 0/54 | 0/55 | 1/110 | 1/110 |
| Pancreatitis acuteGastrointestinal disorders | 0/54 | 0/55 | 0/110 | 1/110 |
| Colonoscopy abnormalInvestigations | 0/54 | 0/55 | 0/110 | 1/110 |
| Endoscopy gastrointestinal abnormalInvestigations | 0/54 | 0/55 | 0/110 | 1/110 |
| Event | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 2/54 | 3/55 | 8/110 | 11/110 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/54 | 1/55 | 7/110 | 1/110 |
| Back painMusculoskeletal and connective tissue disorders | 0/54 | 1/55 | 2/110 | 6/110 |
| DizzinessNervous system disorders | 1/54 | 3/55 | 0/110 | 4/110 |
| HeadacheNervous system disorders | 1/54 | 3/55 | 4/110 | 5/110 |
| Age, Continuous(years) | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM | Total |
|---|---|---|---|---|---|
| Mean | 51.1 ± 14.1 | 46.8 ± 12.1 | 52.3 ± 12.6 | 51.9 ± 12.0 | 51.1 ± 12.7 |
| Sex: Female, Male(Participants) | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM | Total |
|---|---|---|---|---|---|
| Female | 25 | 24 | 45 | 46 | 140 |
| Male | 30 | 31 | 66 | 64 | 191 |
| Race/Ethnicity, Customized(participants) | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 3 | 4 | 8 | 16 |
| Black or African American | 1 | 0 | 1 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| White | 51 | 49 | 100 | 98 | 298 |
| Other | 2 | 3 | 6 | 3 | 14 |
| Race/Ethnicity, Customized(participants) | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 1 | 2 |
| Not Hispanic or Latino | 54 | 55 | 111 | 109 | 329 |
| Stratification Factor: Low-Density Lipoprotein Cholesterol (LDL-C) Level(participants) | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM | Total |
|---|---|---|---|---|---|
| < 160 mg/dL | 35 | 35 | 70 | 70 | 210 |
| ≥ 160 mg/dL | 20 | 20 | 41 | 40 | 121 |
| Baseline Ezetimibe Use(participants) | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM | Total |
|---|---|---|---|---|---|
| No | 22 | 21 | 43 | 43 | 129 |
| Yes | 33 | 34 | 68 | 67 | 202 |
| LDL-C Concentration(mg/dL) | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM | Total |
|---|---|---|---|---|---|
| Mean | 151.1 ± 36.5 | 151.5 ± 42.5 | 161.4 ± 51.0 | 153.6 ± 43.3 | 155.5 ± 44.9 |
| Non-High-Density Lipoprotein Cholesterol (non-HDL-C) Concentration(mg/dL) | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM | Total |
|---|---|---|---|---|---|
| Mean | 175.4 ± 43.9 | 175.4 ± 45.9 | 187.4 ± 56.7 | 178.5 ± 45.8 | 180.4 ± 49.5 |
7 further baseline measures are reported on the registry.
Ran from Feb 2013 to primary completion in Nov 2013, 9 months.
Results were first posted in Dec 2015, 2 years after primary completion. A results delay was requested in May 2014.
Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 9 months is below that.
Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evolocumab